000 04581nam a22007217a 4500
008 201231s20202020 xxu||||| |||| 00| 0 eng d
022 _a2328-9503
024 _a10.1002/acn3.51243 [doi]
024 _aPMC7732242 [pmc]
040 _aOvid MEDLINE(R)
099 _a33216462
245 _aCardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies.
251 _aAnnals of Clinical & Translational Neurology. 7(12):2450-2460, 2020 12.
252 _aAnn. clin. transl. neurol.. 7(12):2450-2460, 2020 12.
252 _zAnn. clin. transl. neurol.. 2020 Nov 20
253 _aAnnals of clinical and translational neurology
260 _c2020
260 _fFY2021
265 _saheadofprint
265 _sppublish
266 _d2020-12-31
268 _aAnnals of Clinical & Translational Neurology. 2020 Nov 20
269 _fFY2021
520 _aINTERPRETATION: By in vivo sympathetic neuroimaging and postmortem neurochemistry peripheral noradrenergic deficiency in LB synucleinopathies is cardioselective. MSA does not involve peripheral noradrenergic deficiency. Copyright (c) 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
520 _aMETHODS: 18 F-DA-derived radioactivity in the heart, liver, spleen, pancreas, stomach, kidneys, thyroid, and submandibular glands were analyzed from 145 patients with LB synucleinopathies (112 PD, 33 PAF), 74 controls, and 85 MSA patients. In largely separate cohorts, postmortem tissue norepinephrine data were reviewed for heart, liver, spleen, pancreas, kidney, thyroid, submandibular gland, and sympathetic ganglion tissue from 38 PD, 2 PAF, and 5 MSA patients and 35 controls.
520 _aOBJECTIVE: Lewy body (LB) synucleinopathies such as Parkinson's disease (PD) entail profound cardiac norepinephrine deficiency. The status of sympathetic noradrenergic innervation at other extracranial sites has been unclear. Although in vivo neuroimaging studies have indicated a cardioselective noradrenergic lesion, no previous study has surveyed peripheral organs for norepinephrine contents in LB diseases. We reviewed 18 F-dopamine (18 F-DA) positron emission tomographic images and postmortem neurochemical data across several body organs of controls and patients with the LB synucleinopathies PD and pure autonomic failure (PAF) and the non-LB synucleinopathy multiple system atrophy (MSA).
520 _aRESULTS: Interventricular septal 18 F-DA-derived radioactivity was decreased in the LB synucleinopathy group compared to the control and MSA groups (P < 0.0001 each). The LB and non-LB groups did not differ in liver, spleen, pancreas, stomach, or kidney 18 F-DA-derived radioactivity. The LB synucleinopathy group had markedly decreased apical myocardial norepinephrine, but normal tissue norepinephrine in other organs. The MSA group had normal tissue norepinephrine in all examined organs.
546 _aEnglish
650 _a*Dopamine/pk [Pharmacokinetics]
650 _a*Heart/dg [Diagnostic Imaging]
650 _a*Lewy Body Disease/me [Metabolism]
650 _a*Multiple System Atrophy/me [Metabolism]
650 _a*Myocardium/me [Metabolism]
650 _a*Norepinephrine/me [Metabolism]
650 _a*Parkinson Disease/me [Metabolism]
650 _a*Pure Autonomic Failure/me [Metabolism]
650 _a*Sympathetic Nervous System/me [Metabolism]
650 _aAged
650 _aAutopsy
650 _aFemale
650 _aFluorine Radioisotopes
650 _aHeart Septum/dg [Diagnostic Imaging]
650 _aHeart Septum/me [Metabolism]
650 _aHeart Ventricles/dg [Diagnostic Imaging]
650 _aHeart Ventricles/me [Metabolism]
650 _aHeart/ir [Innervation]
650 _aHumans
650 _aLewy Body Disease/dg [Diagnostic Imaging]
650 _aMale
650 _aMiddle Aged
650 _aMultiple System Atrophy/dg [Diagnostic Imaging]
650 _aParkinson Disease/dg [Diagnostic Imaging]
650 _aPositron-Emission Tomography
650 _aPure Autonomic Failure/dg [Diagnostic Imaging]
650 _aSympathetic Nervous System/dg [Diagnostic Imaging]
651 _aMedStar Washington Hospital Center
656 _aNeurology
657 _aJournal Article
700 _aLenka, Abhishek
790 _aGoldstein DS, Holmes C, Lamotte G, Lenka A, Sullivan P
856 _uhttps://dx.doi.org/10.1002/acn3.51243
_zhttps://dx.doi.org/10.1002/acn3.51243
942 _cART
_dArticle
999 _c5940
_d5940